Navigation Links
Researchers create new experimental vaccine against chikungunya virus
Date:8/12/2011

GALVESTON Researchers have developed a new candidate vaccine to protect against chikungunya virus, a mosquito-borne pathogen that produces an intensely painful and often chronic arthritic disease that has stricken millions of people in India, Southeast Asia and Africa.

A single dose of the experimental vaccine protected lab mice from infection with the virus, according to a paper published online in the journal PLoS Pathogens by researchers from the University of Texas Medical Branch at Galveston, Inviragen, Inc., of Ft. Collins, Colorado, the University of Wisconsin, the Centers for Disease Control and Prevention and the University of Alabama.

"Currently, we have no approved treatment or vaccine for chikungunya, and there's a real need for an effective vaccine to protect against this debilitating and economically devastating infection," said Scott Weaver, director of UTMB's Institute for Human Infections and Immunity, scientific director of the Galveston National Laboratory and senior author of the paper. "Everything we've seen so far suggests this vaccine candidate could fill that need."

The experimental vaccine is a "recombinant live-attenuated vaccine" created by genetically modifying the chikungunya virus using techniques developed with the initial support from the Western Regional Center of Excellence in Biodefense and Emerging Infectious Diseases, headquartered at UTMB. The resulting vaccine strain differs from wild-type chikungunya virus in two ways: it doesn't cause disease, and it's incapable of infecting mosquitoes; the latter trait is an important safety feature to ensure that the vaccine strain cannot initiate transmission in nonendemic locations where travelers might be immunized before a trip to Africa or Asia. But it still provokes an immune response to protect against future chikungunya infections.

Such a live virus vaccine would also be relatively economical to produce in large quantities an important factor given the limited resources available in the areas hit hardest by chikungunya.

"We need to slow this virus down in India and Southeast Asia, not just to protect the people there but to reduce the very real risk that it might become endemic here after an infected traveler arrives," Weaver said. "The best way to do that is with a vaccine, and if you're going to make a vaccine you have to look at where it's going to be used and what they can afford."

UTMB has signed a license agreement with Inviragen for commercialization of the new vaccine candidate. In addition, the two partners have been chosen to receive a four-year, $3 million grant from the National Institutes of Health to complete the preclinical development work needed submit an investigational new drug application to the Food and Drug Administration, opening the door to human trials.


'/>"/>

Contact: Jim Kelly
jpkelly@utmb.edu
409-772-8791
University of Texas Medical Branch at Galveston
Source:Eurekalert

Related medicine news :

1. Researchers map all the fragile sites of the yeast Saccharomyces cerevisiaes genome
2. UH Case Medical Center researchers publish promising findings for advanced cervical cancer
3. Researchers discover new way to kill pediatric brain tumors
4. Researchers Who Discovered First Genes for Stuttering will Present Findings to the National Stuttering Association
5. Researchers create drug to keep tumor growth switched off
6. Urine protein test might help diagnose kidney damage from lupus, UT Southwestern researchers find
7. GUMC researchers say flower power may reduce resistance to breast cancer drug tamoxifen
8. Clemson researchers develop hands-free texting application
9. Researchers find biomarkers in saliva for detection of early-stage pancreatic cancer
10. Researchers chart genomic map spanning over 2 dozen cancers
11. Researchers discover second protective role for tumor-suppressor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for care ... is the 90-day elimination period, when the family pays for care, is often waived, ...
(Date:10/13/2017)... ... 2017 , ... Global Healthcare Management’s 4th Annual Kids Fun Run brought out ... free event, sponsored by Global Healthcare Management’s CEO, Jon Letko, is aimed at getting ... children of all ages; it is a non-competitive, non-timed event, which is all about ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... Software Development, has been awarded a contract by the Center for Medicare and ... aims to accelerate the enterprise use of Agile methodologies in a consistent and ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... for healthcare compliance program management, will showcase a range of technology and learning ... Assisted Living (NCAL) Convention and Expo to be held October 14–18, 2017 at ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company ... of today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every ... meet the highest standard. , These products are also: Gluten Free, Non-GMO, ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... 12, 2017 AVACEN Medical , Inc. (AVACEN) ... their  2017 New Product Innovation Award for Its fibromyalgia ... and secondary medical device market research by Frost & Sullivan,s ... OTC, drug-free pain relief product, the AVACEN 100, offers a ... fibromyalgia widespread pain. ...
(Date:10/11/2017)...  Caris Life Sciences ® , a leading innovator ... precision medicine, today announced that St. Jude Medical Center,s ... (POA) as its 17 th member. Through participation ... Cancer Institute will help develop standards of care and ... making cancer treatment more precise and effective. ...
(Date:10/10/2017)...   West Pharmaceutical Services, Inc. (NYSE: WST), ... administration, today shared the results of a study highlighting ... intradermal administration of polio vaccines. The study results were ... 2017 by Dr. Ondrej Mach , Clinical Trials ... (WHO), and recently published in the journal Vaccine. ...
Breaking Medicine Technology: